Determine the necessary mass, volume, or concentration for preparing a solution.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
A607852-1mg | 1mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | Special Price $11.90 Regular Price $111.90 | |
A607852-5mg | 5mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $278.90 | |
A607852-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $283.90 | |
A607852-25mg | 25mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $767.90 | |
A607852-50mg | 50mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,073.90 |
Synonyms | HY-120384 | compound 20 [PMID: 34464130] | AZD0284 | AZD-0284 | GTPL11711 | 5G4XF6VU2Y | BDBM50575029 | VCH | 1H-Isoindole-1-carboxamide, 2-acetyl-2,3-dihydro-5-(methylsulfonyl)-N-(4-(2,2,2-trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl)phenyl)-, (1R)- | CS |
---|---|
Specifications & Purity | Moligand™, ≥98% |
Storage Temp | Store at -20°C,Argon charged |
Shipped In | Ice chest + Ice pads |
Grade | Moligand™ |
Action Type | AGONIST |
Mechanism of action | Agonist of RAR-related orphan receptor-γ |
Product Description | AZD-0284 is an inverse agonist of the nuclear receptor RORγ. In development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders |
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
IUPAC Name | (1R)-2-acetyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]-5-methylsulfonyl-1,3-dihydroisoindole-1-carboxamide |
---|---|
INCHI | InChI=1S/C21H18F6N2O5S/c1-11(30)29-10-12-9-15(35(2,33)34)7-8-16(12)17(29)18(31)28-14-5-3-13(4-6-14)19(32,20(22,23)24)21(25,26)27/h3-9,17,32H,10H2,1-2H3,(H,28,31)/t17-/m1/s1 |
InChi Key | QYYZXEPEVBXNNA-QGZVFWFLSA-N |
Canonical SMILES | CC(=O)N1CC2=C(C1C(=O)NC3=CC=C(C=C3)C(C(F)(F)F)(C(F)(F)F)O)C=CC(=C2)S(=O)(=O)C |
Isomeric SMILES | CC(=O)N1CC2=C([C@@H]1C(=O)NC3=CC=C(C=C3)C(C(F)(F)F)(C(F)(F)F)O)C=CC(=C2)S(=O)(=O)C |
Alternate CAS | 2101291-07-8 |
PubChem CID | 129205086 |
MeSH Entry Terms | 2-acetyl-N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)-5-(methylsulfonyl)-2,3-dihydro-1H-isoindole-1-carboxamide;AZD-0284;AZD0284 |
Molecular Weight | 524.43 |
PubChem CID | 129205086 |
---|---|
CAS Registry No. | 2101291-07-8 |
RCSB PDB Ligand | VCH |
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
B2427040 | Certificate of Analysis | Jan 19, 2024 | A607852 |
B2427041 | Certificate of Analysis | Jan 19, 2024 | A607852 |
B2427042 | Certificate of Analysis | Jan 19, 2024 | A607852 |
B2427055 | Certificate of Analysis | Jan 19, 2024 | A607852 |
B2427056 | Certificate of Analysis | Jan 19, 2024 | A607852 |
B2427057 | Certificate of Analysis | Jan 19, 2024 | A607852 |
B2427058 | Certificate of Analysis | Jan 19, 2024 | A607852 |
B2427062 | Certificate of Analysis | Jan 19, 2024 | A607852 |
B2427063 | Certificate of Analysis | Jan 19, 2024 | A607852 |
B2427064 | Certificate of Analysis | Jan 19, 2024 | A607852 |
1. Narjes F, Llinas A, von Berg S, Jirholt J, Lever S, Pehrson R, Collins M, Malmberg M, Svanberg P, Xue Y et al.. (2021) AZD0284, a Potent, Selective, and Orally Bioavailable Inverse Agonist of Retinoic Acid Receptor-Related Orphan Receptor C2. Journal of Medicinal Chemistry, 71 (13): (1755-70). [PMID:34464130] [10.1021/acs.jmedchem.1c01197] |